Fantastic Results:
Viralytics Reports Positive Final Results from CAVATAKTM Phase 2 Melanoma Trial Presentation at American Society for Clinical Oncology Annual Meeting 2015
Primary endpoint achieved with 38.6% (22/57) of late-stage melanoma patients achieved the irPFS1 endpoint
Objective response rate of 28% (16/57) with eight patients achieving complete response2
Durable response3 persisting for at least 6 months in 21% of patients
Activity in non-injected distant lesions, including lung and liver metastases
One-year survival rate of 75.4% with median overall survival4 of 26 months
Well tolerated in 57 patients - no grade 3 or 4 treatment-related adverse events5
Exciting results from biopsy study point to combination synergy with checkpoint inhibitors
- Forums
- ASX - By Stock
- VLA
- Ann: Positive final results from CAVATAK Phase 2 Melanoma Trial
Ann: Positive final results from CAVATAK Phase 2 Melanoma Trial, page-2
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)